OmniAb, Inc. (OABI)

Market Cap	295.57M
Revenue (ttm)	26.39M
Net Income (ttm)	-62.03M
Shares Out	122.13M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	885,450
Open	2.470
Previous Close	2.470
Day's Range	2.405 - 2.500
52-Week Range	2.231 - 5.540
Beta	0.35
Analysts	Strong Buy
Price Target	7.00 (+189.26%)
Earnings Date	Mar 18, 2025

About OABI

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic anim...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 114
• Stock Exchange: NASDAQ
• Ticker Symbol: OABI
• Website: https://www.omniab.com

Financial Performance

In 2024, OmniAb's revenue was $26.39 million, a decrease of -22.75% compared to the previous year's $34.16 million. Losses were -$62.03 million, 22.5% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 189.26% from the latest price.

Price Target

$7.0

(189.26% upside)

Analyst Consensus: Strong Buy